Metabolic · Lyophilized Powder
CAS: 2023788-19-2 | Sequence: 39-aa acylated GIP/GLP-1 analogue | Purity: ≥99.2%
$89.99 / vial
In Stock - Ships Within 24 Hours
SKU PT-TIRZ-10 · HPLC + MS tested every batch · Insulated cold-pack shipping
Tirzepatide is a 39-amino-acid synthetic peptide (4813.45 g/mol) built on the native GIP sequence and engineered to activate both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor — a dual incretin receptor co-agonist.
Two Aib residues (positions 2 and 13) protect it against DPP-4 cleavage, and a C20 fatty diacid on Lys20 provides albumin binding for a multi-day half-life. Researchers use tirzepatide to study dual-incretin pathway activation, receptor signalling bias, and how combined GIP/GLP-1 agonism affects glucose and energy metabolism in preclinical models.
Supplied as 10 mg of lyophilized reference material at ≥99.2% HPLC purity with a batch-specific third-party COA. This is research-grade material, not a drug product — see the regulatory note in the Preclinical Research tab.
Each production lot is independently tested for identity, purity and content. Select a batch to view its analytical results — your vial label lists the batch number.
| Test | Method | Result | Status |
|---|
Technical reference data and a summary of published preclinical literature, provided for educational purposes.
| Name | Tirzepatide |
|---|---|
| Synonyms | LY3298176 |
| CAS Number | 2023788-19-2 |
| Molecular Formula | C225H348N48O68 |
| Molecular Weight | 4813.45 g/mol |
| Sequence (3-letter) | H-Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys-Ile-Ala-Gln-Lys(γGlu-2×OEG-C20 diacid)-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2 |
| Sequence (1-letter) | H-Y(Aib)EGTFTSDYSI(Aib)LDKIAQK(γE-2xOEG-C20 diacid)AFVQWLIAGGPSSGAPPPS-NH2 |
| Structure Class | 39-amino-acid linear peptide based on the native GIP sequence, with Aib at positions 2 and 13 and a C20 fatty diacid on Lys20 via a γGlu–2×OEG linker; C-terminal amide |
| Form | White lyophilized powder |
| Purity | ≥99.2% (RP-HPLC); identity confirmed by ESI-MS |
| Content per Vial | 10 mg net peptide |
| Solubility | Soluble in water and bacteriostatic water; solubility is reduced under acidic conditions |
| Storage Conditions | Lyophilized: −20 °C, desiccated and protected from light. Reconstituted: 2–8 °C, use within 28 days. Swirl gently after reconstitution; acylated peptides are prone to aggregation under vigorous agitation. |
Tirzepatide activates both the GIP and GLP-1 receptors. In vitro characterization describes an "imbalanced" profile: GIP-receptor affinity comparable to native GIP, with weaker GLP-1-receptor affinity than native GLP-1.
At the GLP-1 receptor, tirzepatide favours cAMP generation over β-arrestin recruitment, which has been associated with reduced receptor internalization in cell-based assays.
The C20 fatty diacid moiety supports albumin binding, and the Aib substitutions confer protease resistance, together giving a reported half-life of about five days in humans.
GIP and GLP-1 are the two principal incretin hormones. GIP receptors are expressed on pancreatic β-cells and adipocytes, while GLP-1 receptors are also abundant in the brain and gastrointestinal tract. Co-activating both pathways was hypothesized to produce greater metabolic effects than either alone — the premise tirzepatide was designed to test.
In diet-induced obese mice, tirzepatide reduced food intake and body weight and improved insulin sensitivity to a greater degree than a selective GLP-1 receptor agonist, effects attributed in part to GIP-receptor engagement.
Tirzepatide has been studied in large randomized trials (SURPASS and SURMOUNT programs). Those data relate to the approved pharmaceutical products, not research-grade material.
Representative literature: Coskun T et al., Mol Metab 2018; Willard FS et al., JCI Insight 2020; Jastreboff AM et al., N Engl J Med 2022.
| Diluent Added | Concentration | Per 0.1 mL Aliquot |
|---|---|---|
| 1.0 mL | 10.0 mg/mL | 1 mg |
| 2.0 mL | 5.0 mg/mL | 500 µg |
| 2.5 mL | 4.0 mg/mL | 400 µg |
| 3.0 mL | 3.33 mg/mL | 333 µg |
| 5.0 mL | 2.0 mg/mL | 200 µg |
Allow the vial to reach room temperature. Introduce sterile or bacteriostatic water slowly down the inner glass wall — do not inject directly onto the powder cake. Swirl gently until fully dissolved; do not shake or vortex, as this can promote aggregation.
| State | Condition | Typical Stability |
|---|---|---|
| Lyophilized | −20 °C, desiccated | 24+ months |
| Lyophilized | 2–8 °C | Up to 12 months |
| Lyophilized | Room temp (≤25 °C) | Several weeks (transit) |
| Reconstituted | 2–8 °C | Up to 28 days |
| Reconstituted | −20 °C aliquots | Avoid repeated freeze–thaw |
Storage & Stability
How peptides degrade, why −20 °C and desiccation matter, and practical rules for freeze–thaw cycles, light exposure and reconstituted shelf-life.
Research Review
Single versus dual incretin agonism: how the two most studied incretin analogues differ in structure, receptor signalling and handling — and what that means for assay design.
Complementary research compounds and lab supplies.